Wockhardt Ltd
Wockhardt Ltd Q2 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Wockhardt Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Q1 FY25 EBITDA: INR 213 Cr., representing a 143% year-on-year growth vs Q1 FY24 (Page 12).
From Wockhardt Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. (Page 10)
- Quarterly EBITDA for Q1 FY25 was INR 100 Cr., a 213% growth year-on-year versus Q1 FY24 EBITDA of INR 32 Cr. (Page 12)
- FY24 total income was INR 2,879 Cr., up 7% over FY23 (INR 2,693 Cr.) (Page 10)
- FY24 EBITDA was INR 251 Cr., a 76% growth over FY23 (INR 143 Cr.) (Page 12)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹965 Cr, net profit ₹164 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY25 investor presentation — and how it ranks against sec
- Themis Medicare Ltd (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY25 investor presentation — and how it ranks against sector
- Lincoln Pharmaceuticals Ltd (Q2 FY25)
EBITDA**: ₹1,234 crore, up 15% YoY . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation — and how it ranks aga
- Fermenta Biotech Ltd (Q2 FY25)
Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) . Key investor presentation takeaways from Fermenta Biotech Ltd's Q2 FY25 inv
Frequently Asked Questions
What were Wockhardt Ltd Q2 FY25 results?
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Q1 FY25 EBITDA: INR 213 Cr., representing a 143% year-on-year growth vs Q1 FY24 (Page 12).
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
The investor presentation does not explicitly detail any specific capex amounts, capacity expansion projects, or new plants with timelines and status.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.